Caris Life Sciences (NASDAQ:CAI) Hits New 1-Year Low – Time to Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as $17.12 and last traded at $16.9480, with a volume of 711674 shares changing hands. The stock had previously closed at $18.33.

Analyst Ratings Changes

Several brokerages have recently weighed in on CAI. BTIG Research lowered their price target on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Evercore set a $38.00 target price on Caris Life Sciences in a report on Monday, January 5th. Robert W. Baird increased their target price on Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Caris Life Sciences presently has an average rating of “Hold” and an average target price of $31.50.

Caris Life Sciences Stock Down 7.5%

The stock’s 50 day moving average is $20.93. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The stock has a market cap of $4.79 billion and a P/E ratio of -94.17.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The business had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. During the same period in the previous year, the company posted ($1.73) earnings per share. The business’s revenue for the quarter was up 125.4% on a year-over-year basis.

Institutional Investors Weigh In On Caris Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new stake in Caris Life Sciences in the fourth quarter worth about $261,000. PEAK6 LLC increased its holdings in shares of Caris Life Sciences by 6.9% during the fourth quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after acquiring an additional 1,600 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Caris Life Sciences by 14.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after purchasing an additional 1,180,200 shares during the last quarter. Invesco Ltd. boosted its stake in Caris Life Sciences by 28.5% in the 4th quarter. Invesco Ltd. now owns 1,033,115 shares of the company’s stock worth $27,873,000 after purchasing an additional 229,313 shares in the last quarter. Finally, VARCOV Co. acquired a new stake in Caris Life Sciences in the 4th quarter worth approximately $1,080,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.